Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma

Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 /PRNewswire/ — Iterion Therapeutics , a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the first patient has been dosed in a clinical study evaluating tegavivint, a first-in-class inhibitor of the Wnt/β-catenin pathway, in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is sponsored by Emory University, conducted at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and supported by funding from the Peach Bowl LegACy Fund, reflecting strong academic, clinical and philanthropic commitment to advancing new therapies for this rare pediatric cancer.

The release as fetched from its publisher. iteriontherapeutics.com ↗